Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell

Explore clinical trials studying Lymphoma, B-Cell. Study availability and eligibility vary by location and protocol.

1,618 public trials 340 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell trial results

Completed

Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma

NCT02112526

Conditions
Activated B-cell Diffuse Large B-Cell Lymphoma (ABC DLBCL), Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Research Site Los Angeles, California, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site New York, United States
  • Research Site Columbus, Ohio, United States
View Trial Details
Completed

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

NCT05233033

Conditions
DLBCL, Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, +12 more
Locations
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Henry Ford Health System Detroit, Michigan, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
View Trial Details
Completed

Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma

NCT03846427

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +10 more
Locations
  • Clinical Research Alliance, Inc Westbury, New York, United States
  • The Charlotte Mecklenburg Hospital Authority Charlotte, North Carolina, United States
  • Canberra Hospital Garran, Australian Capital Territory, Australia
  • Concord Repatriation General Hospital Concord, New South Wales, Australia
View all 31 locations
View Trial Details
Completed

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

NCT03955783

Conditions
Acute Myeloid Leukemia, Diffuse Large B-cell Lymphoma, Hematologic Diseases, +15 more
Locations
  • Roswell Park Cancer Center Buffalo, New York, United States
  • University Hospitals of Cleveland Cleveland, Ohio, United States
  • Vanderbilt-Ingram Cancer Center Nashville, Tennessee, United States
  • University of Texas Southwestern Medical Center Dallas, Texas, United States
View Trial Details
Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

NCT03520920

Conditions
Diffuse Large B-cell Lymphoma, Follicular Lymphoma, Hemic and Lymphatic Diseases, +13 more
Locations
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology Wuhan, Hubei, China
  • The Affiliated Hospital of Xuzhou Medical University Xuzhou, Jiangsu, China
  • Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai Municipality, China
View Trial Details
Completed

Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma

NCT03145064

Conditions
Diffuse Large B-cell Lymphoma, Disease Attributes, Hemic and Lymphatic Diseases, +13 more
Locations
  • Beijing Cancer Hospital Beijing, Beijing Municipality, China
  • Harbin Medical University Cancer Hospital Harbin, Heilongjiang, China
  • Henan Cancer Hospital Zhengzhou, Henan, China
  • The First Affiliated Hospital of Soochow University Branch Shizi Suzhou, Jiangsu, China
View Trial Details

Related conditions